UTHR
Companies
NASDAQ
United Therapeutics Corporation
Health Care
$291.72
-$61.12 (-17.32%)
Price Chart
Overview
About UTHR
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Market Cap
$12.2B
Volume
136.8M
Avg. Volume
167.2M
P/E Ratio
10.031923
Dividend Yield
0.00%
Employees
1.1K
Company Information
Risk & Correlation Analysis
Market Correlation
0.55
Low Correlation
Volatility
Medium (0.32)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, UTHR shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$12.2B
Volume136.8M
P/E Ratio10.03
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 26, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025